文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

适应性免疫微环境在接受5-氮杂胞苷治疗的高危骨髓增生异常综合征患者中的预后作用

Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine.

作者信息

Tsakiraki Zoi, Spathis Aris, Bouchla Anthi, Pouliakis Abraham, Vryttia Pinelopi, Panayiotides Ioannis G, Pappa Vasiliki, Papageorgiou Sotiris G, Foukas Periklis G

机构信息

2nd Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.

Hematology Unit, 2nd Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.

出版信息

Cancers (Basel). 2025 Mar 25;17(7):1104. doi: 10.3390/cancers17071104.


DOI:10.3390/cancers17071104
PMID:40227622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11988087/
Abstract

BACKGROUND/OBJECTIVES: There are limited data regarding immunohistochemical profiling of immune cells in bone marrow trephine biopsies of patients with high-risk myelodysplastic syndromes (HR-MDS). METHODS: We sought to objectively quantify, with the use of digital pathology, the density (cells/mm2) of the prominent adaptive immunity cell populations in sixty-four (64) bone marrow trephine biopsies of HR-MDS patients receiving 5-Azacytidine. We focused on CD3(+) T cells, CD8(+) cytotoxic T cells (Tc), helper T cells (Th), Foxp3(+) regulatory T cells (Tregs), CD20(+) B-cells and CD138(+) plasma cells and evaluated the presence and the number of lymphoid aggregates. A control group of twenty "non-MDS" patients was included in the study. RESULTS: We identified a significant decrease in adaptive immune cell densities in the HR-MDS patients compared to the non-MDS controls. Increased T and Th cell densities correlated with the response to 5-Azacytidine (5-AZA) treatment. Higher T, Tc, Th and plasma cells densities and low B, Tregs and Tregs/T cells ratios correlated with increased overall survival. Reduced Tregs, Tregs/T cells, Tregs/Tc and plasma cells showed improved leukemia-free survival. A modified IPSS-R (IPSS-R-I), combining the initial IPSS-R with the immune populations' parameters, improved overall survival and showed a double-fold increase in Cox calculated hazard ratios. CONCLUSIONS: Immunohistochemical bone marrow immune profiling represents a powerful and easily useable tool for investigating the possible role of bone marrow immune microenvironment in the pathogenesis and progression of MDS, but also its association with the response to 5-AZA treatment and clinical outcomes.

摘要

背景/目的:关于高危骨髓增生异常综合征(HR-MDS)患者骨髓活检组织中免疫细胞免疫组化分析的数据有限。 方法:我们试图利用数字病理学客观量化64例接受5-氮杂胞苷治疗的HR-MDS患者骨髓活检组织中主要适应性免疫细胞群的密度(细胞/mm²)。我们重点关注CD3(+) T细胞、CD8(+) 细胞毒性T细胞(Tc)、辅助性T细胞(Th)、Foxp3(+) 调节性T细胞(Tregs)、CD20(+) B细胞和CD138(+) 浆细胞,并评估淋巴聚集物的存在和数量。研究纳入了20例“非MDS”患者作为对照组。 结果:我们发现与非MDS对照组相比,HR-MDS患者的适应性免疫细胞密度显著降低。T细胞和Th细胞密度增加与对5-氮杂胞苷(5-AZA)治疗的反应相关。较高的T细胞、Tc细胞、Th细胞和浆细胞密度以及较低的B细胞、Tregs细胞和Tregs/T细胞比值与总生存期延长相关。Tregs细胞、Tregs/T细胞、Tregs/Tc细胞和浆细胞减少表明无白血病生存期改善。一种改良的国际预后评分系统(IPSS-R),将初始IPSS-R与免疫细胞群参数相结合,改善了总生存期,并使Cox计算的风险比增加了两倍。 结论:免疫组化骨髓免疫分析是一种强大且易于使用的工具,可用于研究骨髓免疫微环境在MDS发病机制和进展中的可能作用,以及其与对5-AZA治疗反应和临床结局的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/bdd95a695c3e/cancers-17-01104-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/273555aefdaf/cancers-17-01104-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/65f430e802dd/cancers-17-01104-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/bdd95a695c3e/cancers-17-01104-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/273555aefdaf/cancers-17-01104-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/65f430e802dd/cancers-17-01104-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e4/11988087/bdd95a695c3e/cancers-17-01104-g003.jpg

相似文献

[1]
Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine.

Cancers (Basel). 2025-3-25

[2]
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.

Hematol Oncol. 2020-6-26

[3]
Bone marrow CD3 CD56 regulatory T lymphocytes (T cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS-R very-low/low risk MDS patients.

Eur J Haematol. 2022-10

[4]
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Ther Adv Hematol. 2020-12-8

[5]
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.

Br J Haematol. 2020-8

[6]
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?

Front Oncol. 2023-1-26

[7]
[Effect of Decitabine on Regulatory T Cells Relative Content in Peripheral Blood and Bone Marrow of Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022-2

[8]
Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting.

Oncol Lett. 2020-2

[9]
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Hematol Oncol. 2018-9-7

[10]
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.

Hematol Oncol. 2021-4

本文引用的文献

[1]
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.

Mol Cancer. 2024-4-6

[2]
Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.

Cell Death Dis. 2023-9-4

[3]
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?

Front Oncol. 2023-1-26

[4]
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes.

Cancers (Basel). 2022-11-17

[5]
Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.

Cancers (Basel). 2022-1-5

[6]
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Cytometry B Clin Cytom. 2023-1

[7]
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine.

J Clin Med. 2021-10-20

[8]
WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.

Int J Hematol. 2021-5

[9]
Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34 Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia.

Cancers (Basel). 2021-1-7

[10]
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Ther Adv Hematol. 2020-12-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索